Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

People with heart failure have long been advised to limit the amount of fluids they consume each day to help reduce congestion, or the buildup of fluid in the lungs and extremities, but that advice provides no benefit, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

About The Study: In patients with heart failure and iron deficiency, ferric carboxymaltose did not significantly reduce the time to first heart failure hospitalization or cardiovascular death in the overall cohort or in patients with a transferrin saturation less than 20%, or reduce the total number of heart failure hospitalizations vs placebo.

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely to die or experience worsening heart failure at one year compared with patients who did not take the drug, according to a study presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

About The Study: The efficacy of finerenone was consistent regardless of atrial fibrillation status in this study. New-onset atrial fibrillation was associated with a substantially higher risk of subsequent outcomes.

An intensive three-drug regimen of heart medications did not significantly impact the rate of serious cardiovascular events at five years in women who experienced signs and symptoms of ischemia, or insufficient blood flow to the heart muscle, but had no blockages in their heart’s arteries, according to research presented at the American College of Cardiology’s Annual Scientific Session (ACC.25).

Heart disease remains the leading cause of death in the United States, accounting for one in five deaths. The inability of damaged heart muscle tissue to regenerate makes heart disease difficult to treat, and end-stage heart failure patients have no choice but to join a long list of people waiting for a heart transplant. Researchers from Emory University are working to provide another option for such patients. To do this, the team took their research to a laboratory unlike any on Earth—the International Space Station (ISSInternational Space Station).

Researchers investigated the function of gasdermin D, a key participant in inflammatory pathways, in atrial heart cells and found a potential contribution to atrial fibrillation (AF), which positions gasdermin D as a promising target for novel therapeutic option for this serious heart condition.

American Heart Association’s international Heart Failure Center Certification will recognize hospitals dedicated to optimizing HF treatment, reducing readmissions.